AbCellera said Q1 2026 was marked by progress in its internal drug pipeline, highlighted by interim Phase 1 data for lead program ABCL635. The company also said it is preparing for multiple clinical catalysts over the next two years, pointing to continued pipeline development rather than near-term commercial results.
AbCellera said Q1 2026 was marked by progress in its internal drug pipeline, highlighted by interim Phase 1 data for lead program ABCL635. The company also said it is preparing for multiple clinical catalysts over the next two years, pointing to continued pipeline development rather than near-term commercial results.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
